| NCT03240133 |
Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema |
https://ClinicalTrials.gov/show/NCT03240133 |
Completed |
BioCryst Pharmaceuticals |
2019-01-29 |
| NCT03202784 |
A Relative Bioavailability Study of Two Formulations of BCX7353 |
https://ClinicalTrials.gov/show/NCT03202784 |
Completed |
BioCryst Pharmaceuticals |
2017-08-01 |
| NCT03136237 |
A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions |
https://ClinicalTrials.gov/show/NCT03136237 |
Completed |
BioCryst Pharmaceuticals |
2017-08-15 |
| NCT02966314 |
Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy |
https://ClinicalTrials.gov/show/NCT02966314 |
Completed |
University of Wisconsin, Madison |
2020-01-06 |
| NCT02892682 |
The Role of the Coagulation Pathways in Recurrent Angioedema |
https://ClinicalTrials.gov/show/NCT02892682 |
Recruiting |
University Hospital, Montpellier |
2021-05-31 |
| NCT02865720 |
Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE) |
https://ClinicalTrials.gov/show/NCT02865720 |
Completed |
Shire |
2017-06-23 |
| NCT02819102 |
An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates |
https://ClinicalTrials.gov/show/NCT02819102 |
Completed |
BioCryst Pharmaceuticals |
2016-06-30 |
| NCT02663687 |
Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects |
https://ClinicalTrials.gov/show/NCT02663687 |
Completed |
Shire |
2016-12-05 |
| NCT02586805 |
Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE |
https://ClinicalTrials.gov/show/NCT02586805 |
Completed |
Shire |
2017-04-13 |
| NCT02448264 |
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers |
https://ClinicalTrials.gov/show/NCT02448264 |
Completed |
BioCryst Pharmaceuticals |
2015-11-30 |
| NCT02316353 |
A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema |
https://ClinicalTrials.gov/show/NCT02316353 |
Completed |
CSL Behring |
2017-09-21 |
| NCT02303626 |
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks |
https://ClinicalTrials.gov/show/NCT02303626 |
Completed |
BioCryst Pharmaceuticals |
2016-01-31 |
| NCT02247739 |
A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor |
https://ClinicalTrials.gov/show/NCT02247739 |
Completed |
Pharming Technologies B.V. |
2016-05-31 |
| NCT02218294 |
Study to Determine How BCX4161 is Metabolized and Eliminated by the Body |
https://ClinicalTrials.gov/show/NCT02218294 |
Completed |
BioCryst Pharmaceuticals |
2014-09-30 |
| NCT02125162 |
A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161 |
https://ClinicalTrials.gov/show/NCT02125162 |
Completed |
BioCryst Pharmaceuticals |
2014-07-31 |
| NCT02093923 |
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema (HAE) Subjects |
https://ClinicalTrials.gov/show/NCT02093923 |
Completed |
Shire |
2015-05-31 |
| NCT02052141 |
Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema |
https://ClinicalTrials.gov/show/NCT02052141 |
Completed |
Shire |
2017-05-04 |
| NCT02045264 |
Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers |
https://ClinicalTrials.gov/show/NCT02045264 |
Completed |
Shire |
2014-02-28 |
| NCT01984788 |
Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE |
https://ClinicalTrials.gov/show/NCT01984788 |
Completed |
BioCryst Pharmaceuticals |
2014-05-31 |
| NCT01923207 |
A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects |
https://ClinicalTrials.gov/show/NCT01923207 |
Completed |
Shire |
2014-01-07 |
| NCT01919801 |
Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema |
https://ClinicalTrials.gov/show/NCT01919801 |
Completed |
Shire |
2015-08-22 |
| NCT01912456 |
A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema |
https://ClinicalTrials.gov/show/NCT01912456 |
Completed |
CSL Behring |
2015-10-31 |
| NCT01760343 |
A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor |
https://ClinicalTrials.gov/show/NCT01760343 |
Completed |
CSL Behring |
2013-03-31 |
| NCT01756157 |
Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks |
https://ClinicalTrials.gov/show/NCT01756157 |
Completed |
Shire |
2013-09-13 |
| NCT01723072 |
Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy |
https://ClinicalTrials.gov/show/NCT01723072 |
Completed |
Novartis |
2014-05-31 |
| NCT01679912 |
A Call Center During HAE Attacks (SOS HAE) |
https://ClinicalTrials.gov/show/NCT01679912 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2016-09-30 |
| NCT01576523 |
A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route |
https://ClinicalTrials.gov/show/NCT01576523 |
Completed |
CSL Behring |
2012-12-31 |
| NCT01467947 |
Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert |
https://ClinicalTrials.gov/show/NCT01467947 |
Completed |
CSL Behring |
2014-10-31 |
| NCT01457430 |
Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE |
https://ClinicalTrials.gov/show/NCT01457430 |
Completed |
Massachusetts General Hospital |
2014-04-30 |
| NCT01426763 |
A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase |
https://ClinicalTrials.gov/show/NCT01426763 |
Completed |
Shire |
2011-11-30 |
| NCT01413542 |
Pharmacogenetics of Ace Inhibitor-Associated Angioedema |
https://ClinicalTrials.gov/show/NCT01413542 |
Completed |
Vanderbilt University |
2013-07-31 |
| NCT01386658 |
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema |
https://ClinicalTrials.gov/show/NCT01386658 |
Completed |
Shire |
2018-03-12 |
| NCT01371877 |
The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment |
https://ClinicalTrials.gov/show/NCT01371877 |
Completed |
University of Nebraska |
2013-09-30 |
| NCT01359969 |
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients |
https://ClinicalTrials.gov/show/NCT01359969 |
Completed |
Pharming Technologies B.V. |
2017-07-17 |
| NCT04349800 |
A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 in Healthy Volunteers |
https://ClinicalTrials.gov/show/NCT04349800 |
Completed |
KalVista Pharmaceuticals, Ltd. |
2018-09-10 |
| NCT04307381 |
An Extension Study of IONIS-PKK-LRx in Participants With Hereditary Angioedema |
https://ClinicalTrials.gov/show/NCT04307381 |
Recruiting |
Ionis Pharmaceuticals, Inc. |
2021-12-06 |
| NCT04208412 |
A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II |
https://ClinicalTrials.gov/show/NCT04208412 |
Recruiting |
KalVista Pharmaceuticals, Ltd. |
2020-09-30 |
| NCT04206605 |
Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) and Acquired Angioedema (AAE) Due to C1-INH Deficiency |
https://ClinicalTrials.gov/show/NCT04206605 |
Active, not recruiting |
Shire |
2023-03-03 |
| NCT04180163 |
Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE) |
https://ClinicalTrials.gov/show/NCT04180163 |
Recruiting |
Shire |
2021-12-31 |
| NCT04070326 |
A Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Pediatric Participants of 2 Years to Less Than (<) 12 Years of Age |
https://ClinicalTrials.gov/show/NCT04070326 |
Active, not recruiting |
Shire |
2021-12-17 |
| NCT04032002 |
Involvement of Monocytic B1 and B2 Receptors in Inflammation and Chronic Vascular Disease in Patients With Hereditary Bradykinetic Angioedema |
https://ClinicalTrials.gov/show/NCT04032002 |
Recruiting |
University Hospital, Rouen |
2021-09-30 |
| NCT03917680 |
Evaluation of New Markers in Type 3 Angioedema |
https://ClinicalTrials.gov/show/NCT03917680 |
Completed |
Brugmann University Hospital |
2019-10-08 |
| NCT03888755 |
A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants |
https://ClinicalTrials.gov/show/NCT03888755 |
Completed |
Shire |
2016-02-12 |
| NCT03873116 |
Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan |
https://ClinicalTrials.gov/show/NCT03873116 |
Active, not recruiting |
BioCryst Pharmaceuticals |
2019-11-30 |
| NCT03749135 |
Dupilumab in Chronic Spontaneous Urticaria |
https://ClinicalTrials.gov/show/NCT03749135 |
Recruiting |
Charite University, Berlin, Germany |
2020-10-31 |
| NCT03545464 |
COrticosteroids in acUte uRticAria in emerGency dEpartment |
https://ClinicalTrials.gov/show/NCT03545464 |
Recruiting |
Assistance Publique - Hôpitaux de Paris |
2020-11-15 |
| NCT03485911 |
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE |
https://ClinicalTrials.gov/show/NCT03485911 |
Active, not recruiting |
BioCryst Pharmaceuticals |
2019-04-10 |
| NCT03472040 |
A Long Term Safety Study of BCX7353 in Hereditary Angioedema |
https://ClinicalTrials.gov/show/NCT03472040 |
Recruiting |
BioCryst Pharmaceuticals |
2024-02-29 |
| NCT01188564 |
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks |
https://ClinicalTrials.gov/show/NCT01188564 |
Completed |
Pharming Technologies B.V. |
2012-12-31 |
| NCT01154361 |
AMelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study |
https://ClinicalTrials.gov/show/NCT01154361 |
Completed |
Technische Universität München |
NA |
| NCT01095510 |
CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12 |
https://ClinicalTrials.gov/show/NCT01095510 |
Completed |
Shire |
2012-04-17 |
| NCT01095497 |
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration |
https://ClinicalTrials.gov/show/NCT01095497 |
Completed |
Shire |
2010-12-31 |
| NCT01005888 |
C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks |
https://ClinicalTrials.gov/show/NCT01005888 |
Completed |
Shire |
2007-05-31 |
| NCT00997204 |
EASSI - Evaluation of the Safety of Self-Administration With Icatibant |
https://ClinicalTrials.gov/show/NCT00997204 |
Completed |
Shire |
2011-06-30 |
| NCT00914966 |
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE |
https://ClinicalTrials.gov/show/NCT00914966 |
Completed |
Shire |
2012-05-31 |
| NCT00912093 |
A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3) |
https://ClinicalTrials.gov/show/NCT00912093 |
Completed |
Shire |
2012-07-31 |
| NCT00890162 |
A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis |
https://ClinicalTrials.gov/show/NCT00890162 |
Completed |
National Institutes of Health Clinical Center (CC) |
2018-07-31 |
| NCT00851409 |
A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration |
https://ClinicalTrials.gov/show/NCT00851409 |
Completed |
Pharming Technologies B.V. |
2010-03-31 |
| NCT02741596 |
Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE |
https://ClinicalTrials.gov/show/NCT02741596 |
Completed |
Shire |
2019-10-31 |
| NCT02870972 |
Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema |
https://ClinicalTrials.gov/show/NCT02870972 |
Completed |
BioCryst Pharmaceuticals |
2017-08-31 |
| NCT01826916 |
EDEMA2: Evaluation of DX-88’s Effect in Mitigating Angioedema |
https://ClinicalTrials.gov/show/NCT01826916 |
Completed |
Shire |
2005-12-01 |
| NCT02584959 |
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema |
https://ClinicalTrials.gov/show/NCT02584959 |
Completed |
Shire |
2017-07-24 |
| NCT04030598 |
A Study to Assess the Clinical Efficacy of IONIS-PKK-LRx in Participants With Hereditary Angioedema |
https://ClinicalTrials.gov/show/NCT04030598 |
Recruiting |
Ionis Pharmaceuticals, Inc. |
2020-11-30 |
| NCT03712228 |
A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE) |
https://ClinicalTrials.gov/show/NCT03712228 |
Active, not recruiting |
CSL Behring |
2021-10-14 |
| NCT00748202 |
Berinert P Study of Subcutaneous Versus Intravenous Administration |
https://ClinicalTrials.gov/show/NCT00748202 |
Completed |
Johann Wolfgang Goethe University Hospital |
2010-12-31 |
| NCT00500656 |
Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE) |
https://ClinicalTrials.gov/show/NCT00500656 |
Completed |
Shire |
2008-03-31 |
| NCT00462709 |
Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks |
https://ClinicalTrials.gov/show/NCT00462709 |
Completed |
Shire |
2009-03-31 |
| NCT00456508 |
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE) |
https://ClinicalTrials.gov/show/NCT00456508 |
Completed |
Shire |
2010-06-01 |
| NCT00457015 |
Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE) |
https://ClinicalTrials.gov/show/NCT00457015 |
Completed |
Shire |
2008-06-01 |
| NCT00438815 |
Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks |
https://ClinicalTrials.gov/show/NCT00438815 |
Completed |
Shire |
2009-03-31 |
| NCT00432510 |
Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects |
https://ClinicalTrials.gov/show/NCT00432510 |
Completed |
Shire |
2007-03-31 |
| NCT00385372 |
Significance of an Elimination and Provocation Diet in Patients With Chronic Urticaria |
https://ClinicalTrials.gov/show/NCT00385372 |
Completed |
University Hospital Muenster |
2007-01-31 |
| NCT00292981 |
C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study) |
https://ClinicalTrials.gov/show/NCT00292981 |
Completed |
CSL Behring |
2010-02-28 |
| NCT00289211 |
C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks |
https://ClinicalTrials.gov/show/NCT00289211 |
Completed |
Shire |
2006-12-31 |
| NCT00262301 |
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema |
https://ClinicalTrials.gov/show/NCT00262301 |
Completed |
Pharming Technologies B.V. |
2009-07-31 |
| NCT00262288 |
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema |
https://ClinicalTrials.gov/show/NCT00262288 |
Completed |
Pharming Technologies B.V. |
2007-01-31 |
| NCT00262080 |
Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE) |
https://ClinicalTrials.gov/show/NCT00262080 |
Completed |
Shire |
2005-12-31 |
| NCT00261053 |
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema |
https://ClinicalTrials.gov/show/NCT00261053 |
Completed |
Pharming Technologies B.V. |
2005-09-30 |
| NCT00225147 |
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema |
https://ClinicalTrials.gov/show/NCT00225147 |
Completed |
Pharming Technologies B.V. |
2009-10-31 |
| NCT00168103 |
Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks |
https://ClinicalTrials.gov/show/NCT00168103 |
Completed |
CSL Behring |
2007-10-31 |
| NCT00125541 |
C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema |
https://ClinicalTrials.gov/show/NCT00125541 |
Completed |
Sanquin Plasma Products BV |
2008-04-30 |
| NCT00125151 |
C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema |
https://ClinicalTrials.gov/show/NCT00125151 |
Completed |
Sanquin Plasma Products BV |
NA |
| NCT00119431 |
Kinetics, Efficacy and Safety of C1-Esteraseremmer-N |
https://ClinicalTrials.gov/show/NCT00119431 |
Completed |
Sanquin Plasma Products BV |
NA |
| NCT00097695 |
Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema |
https://ClinicalTrials.gov/show/NCT00097695 |
Completed |
Shire |
2008-03-31 |
| NCT00004694 |
Study of Heparin Prophylaxis of Hereditary Angioedema Exacerbations |
https://ClinicalTrials.gov/show/NCT00004694 |
Completed |
FDA Office of Orphan Products Development |
NA |